HRP20120715T1 - Derivati (tio)karbamoil-cikloheksana kao antagonisti d3/d2 receptora - Google Patents
Derivati (tio)karbamoil-cikloheksana kao antagonisti d3/d2 receptora Download PDFInfo
- Publication number
- HRP20120715T1 HRP20120715T1 HRP20120715TT HRP20120715T HRP20120715T1 HR P20120715 T1 HRP20120715 T1 HR P20120715T1 HR P20120715T T HRP20120715T T HR P20120715TT HR P20120715 T HRP20120715 T HR P20120715T HR P20120715 T1 HRP20120715 T1 HR P20120715T1
- Authority
- HR
- Croatia
- Prior art keywords
- ethyl
- cyclohexyl
- trans
- phenyl
- piperazin
- Prior art date
Links
- JMMKXVYQBRGGJF-UHFFFAOYSA-N cyclohexanecarbothioamide Chemical class NC(=S)C1CCCCC1 JMMKXVYQBRGGJF-UHFFFAOYSA-N 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 14
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims abstract 10
- 150000004677 hydrates Chemical class 0.000 claims abstract 9
- 150000003839 salts Chemical class 0.000 claims abstract 9
- 239000012453 solvate Substances 0.000 claims abstract 9
- 125000003118 aryl group Chemical group 0.000 claims abstract 7
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 7
- 125000000217 alkyl group Chemical group 0.000 claims abstract 6
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 6
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000001589 carboacyl group Chemical group 0.000 claims abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 4
- 239000001257 hydrogen Substances 0.000 claims abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 4
- 150000002431 hydrogen Chemical class 0.000 claims abstract 4
- 239000001301 oxygen Substances 0.000 claims abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims abstract 3
- 125000003342 alkenyl group Chemical group 0.000 claims abstract 3
- 229910052736 halogen Inorganic materials 0.000 claims abstract 3
- 150000002367 halogens Chemical class 0.000 claims abstract 3
- 125000005842 heteroatom Chemical group 0.000 claims abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 3
- 125000002950 monocyclic group Chemical group 0.000 claims abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 3
- 229920006395 saturated elastomer Polymers 0.000 claims abstract 3
- 125000004434 sulfur atom Chemical group 0.000 claims abstract 3
- 125000003435 aroyl group Chemical group 0.000 claims abstract 2
- 125000002619 bicyclic group Chemical group 0.000 claims abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 2
- 150000001412 amines Chemical class 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 208000028017 Psychotic disease Diseases 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 238000006243 chemical reaction Methods 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 206010012289 Dementia Diseases 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 238000010976 amide bond formation reaction Methods 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 239000000543 intermediate Substances 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- QNTHRQYZEIGUHC-UHFFFAOYSA-N 1-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-3-ethylurea Chemical compound C1CC(NC(=O)NCC)CCC1CCN1CCN(C=2C(=C(Cl)C=CC=2)Cl)CC1 QNTHRQYZEIGUHC-UHFFFAOYSA-N 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- KPWSJANDNDDRMB-UHFFFAOYSA-N 3-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethylurea Chemical compound C1CC(NC(=O)N(C)C)CCC1CCN1CCN(C=2C(=C(Cl)C=CC=2)Cl)CC1 KPWSJANDNDDRMB-UHFFFAOYSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- APXUZXLRGKXFHI-IYARVYRRSA-N CC(C)(C)NC(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 Chemical compound CC(C)(C)NC(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 APXUZXLRGKXFHI-IYARVYRRSA-N 0.000 claims 1
- RYCFPLPWVOOIPH-IYARVYRRSA-N CC(C)(C)NC(=S)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 Chemical compound CC(C)(C)NC(=S)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 RYCFPLPWVOOIPH-IYARVYRRSA-N 0.000 claims 1
- CSKJYUXPLFAZNF-IYARVYRRSA-N CC(C)NC(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 Chemical compound CC(C)NC(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 CSKJYUXPLFAZNF-IYARVYRRSA-N 0.000 claims 1
- XMJMOXDQEBSNCY-WGSAOQKQSA-N CCCCNC(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 Chemical compound CCCCNC(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 XMJMOXDQEBSNCY-WGSAOQKQSA-N 0.000 claims 1
- PISWPQBLBOQOQI-WGSAOQKQSA-N CCCCNC(=S)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 Chemical compound CCCCNC(=S)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 PISWPQBLBOQOQI-WGSAOQKQSA-N 0.000 claims 1
- OZTAIUUMPHQLTN-WGSAOQKQSA-N CCCN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 Chemical compound CCCN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 OZTAIUUMPHQLTN-WGSAOQKQSA-N 0.000 claims 1
- FBEZFXQWEHBBJG-IYARVYRRSA-N CCCNC(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 Chemical compound CCCNC(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 FBEZFXQWEHBBJG-IYARVYRRSA-N 0.000 claims 1
- LYCDBPRWIBHWLA-IYARVYRRSA-N CCCNC(=S)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 Chemical compound CCCNC(=S)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 LYCDBPRWIBHWLA-IYARVYRRSA-N 0.000 claims 1
- ZSJKRIBBMYIYIU-IYARVYRRSA-N CCN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 Chemical compound CCN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 ZSJKRIBBMYIYIU-IYARVYRRSA-N 0.000 claims 1
- WBUZBTAJFCVQBH-IYARVYRRSA-N CCNC(=O)N[C@H]1CC[C@H](CCN2CCCN(CC2)c2cccc(Cl)c2Cl)CC1 Chemical compound CCNC(=O)N[C@H]1CC[C@H](CCN2CCCN(CC2)c2cccc(Cl)c2Cl)CC1 WBUZBTAJFCVQBH-IYARVYRRSA-N 0.000 claims 1
- MEYREPCOJHUNGA-QAQDUYKDSA-N CCNC(=S)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 Chemical compound CCNC(=S)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 MEYREPCOJHUNGA-QAQDUYKDSA-N 0.000 claims 1
- HNRRFABIEFXITE-IYARVYRRSA-N CCOC(=O)CNC(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 Chemical compound CCOC(=O)CNC(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 HNRRFABIEFXITE-IYARVYRRSA-N 0.000 claims 1
- PHJYZFGJNYLXAE-IYARVYRRSA-N CCOC(=O)CNC(=S)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 Chemical compound CCOC(=O)CNC(=S)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 PHJYZFGJNYLXAE-IYARVYRRSA-N 0.000 claims 1
- ZSONOMOSRJPQHR-QAQDUYKDSA-N CCOC(=O)NC(=S)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 Chemical compound CCOC(=O)NC(=S)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 ZSONOMOSRJPQHR-QAQDUYKDSA-N 0.000 claims 1
- JQWBHRLCVKAZPM-MEMLXQNLSA-N CCOc1ccccc1NC(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 Chemical compound CCOc1ccccc1NC(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 JQWBHRLCVKAZPM-MEMLXQNLSA-N 0.000 claims 1
- VWHYXUVIHOMBIH-IYARVYRRSA-N CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCCN(CC2)c2cccc(Cl)c2Cl)CC1 Chemical compound CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCCN(CC2)c2cccc(Cl)c2Cl)CC1 VWHYXUVIHOMBIH-IYARVYRRSA-N 0.000 claims 1
- MFEKOKTWMVOCHB-MXVIHJGJSA-N CN1CCN(CC1)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 Chemical compound CN1CCN(CC1)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 MFEKOKTWMVOCHB-MXVIHJGJSA-N 0.000 claims 1
- WMQLLTKSISGWHQ-WKILWMFISA-N CNC(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 Chemical compound CNC(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 WMQLLTKSISGWHQ-WKILWMFISA-N 0.000 claims 1
- LIVQOTZDNZLOIJ-CIQKOQMRSA-N COC(=O)C(NC(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1)C(C)C Chemical compound COC(=O)C(NC(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1)C(C)C LIVQOTZDNZLOIJ-CIQKOQMRSA-N 0.000 claims 1
- AHTLPQWPKVOKPU-MXVIHJGJSA-N COc1cc(NC(=O)N[C@H]2CC[C@H](CCN3CCN(CC3)c3cccc(Cl)c3Cl)CC2)cc(OC)c1OC Chemical compound COc1cc(NC(=O)N[C@H]2CC[C@H](CCN3CCN(CC3)c3cccc(Cl)c3Cl)CC2)cc(OC)c1OC AHTLPQWPKVOKPU-MXVIHJGJSA-N 0.000 claims 1
- UYJJVXSUCHQFIV-MXVIHJGJSA-N COc1ccc(NC(=O)N[C@H]2CC[C@H](CCN3CCN(CC3)c3cccc(Cl)c3Cl)CC2)c(OC)c1 Chemical compound COc1ccc(NC(=O)N[C@H]2CC[C@H](CCN3CCN(CC3)c3cccc(Cl)c3Cl)CC2)c(OC)c1 UYJJVXSUCHQFIV-MXVIHJGJSA-N 0.000 claims 1
- CHGPDHQTDAWHAV-MXVIHJGJSA-N COc1ccc(NC(=O)N[C@H]2CC[C@H](CCN3CCN(CC3)c3cccc(Cl)c3Cl)CC2)cc1 Chemical compound COc1ccc(NC(=O)N[C@H]2CC[C@H](CCN3CCN(CC3)c3cccc(Cl)c3Cl)CC2)cc1 CHGPDHQTDAWHAV-MXVIHJGJSA-N 0.000 claims 1
- LVZNPSOOJFVFNG-MXVIHJGJSA-N COc1cccc(NC(=O)N[C@H]2CC[C@H](CCN3CCN(CC3)c3cccc(Cl)c3Cl)CC2)c1 Chemical compound COc1cccc(NC(=O)N[C@H]2CC[C@H](CCN3CCN(CC3)c3cccc(Cl)c3Cl)CC2)c1 LVZNPSOOJFVFNG-MXVIHJGJSA-N 0.000 claims 1
- HPDINVJOQFSXMW-MXVIHJGJSA-N COc1ccccc1NC(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 Chemical compound COc1ccccc1NC(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 HPDINVJOQFSXMW-MXVIHJGJSA-N 0.000 claims 1
- XYUWSXFPXIEBEY-MXVIHJGJSA-N COc1ccccc1NC(=S)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 Chemical compound COc1ccccc1NC(=S)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 XYUWSXFPXIEBEY-MXVIHJGJSA-N 0.000 claims 1
- GXDDSQDRGDWARS-MXVIHJGJSA-N CSc1ccc(NC(=O)N[C@H]2CC[C@H](CCN3CCN(CC3)c3cccc(Cl)c3Cl)CC2)cc1 Chemical compound CSc1ccc(NC(=O)N[C@H]2CC[C@H](CCN3CCN(CC3)c3cccc(Cl)c3Cl)CC2)cc1 GXDDSQDRGDWARS-MXVIHJGJSA-N 0.000 claims 1
- BAKCLFWEDAGXMG-MXVIHJGJSA-N Clc1cccc(N2CCCN(CC[C@H]3CC[C@@H](CC3)NC(=O)N3CCCC3)CC2)c1Cl Chemical compound Clc1cccc(N2CCCN(CC[C@H]3CC[C@@H](CC3)NC(=O)N3CCCC3)CC2)c1Cl BAKCLFWEDAGXMG-MXVIHJGJSA-N 0.000 claims 1
- SJLVGUOJIQGHDY-WGSAOQKQSA-N Clc1cccc(N2CCN(CC[C@H]3CC[C@@H](CC3)NC(=O)N3CCCC3)CC2)c1Cl Chemical compound Clc1cccc(N2CCN(CC[C@H]3CC[C@@H](CC3)NC(=O)N3CCCC3)CC2)c1Cl SJLVGUOJIQGHDY-WGSAOQKQSA-N 0.000 claims 1
- JDADDZFCNPRPPP-MXVIHJGJSA-N Clc1cccc(N2CCN(CC[C@H]3CC[C@@H](CC3)NC(=O)N3CCCCC3)CC2)c1Cl Chemical compound Clc1cccc(N2CCN(CC[C@H]3CC[C@@H](CC3)NC(=O)N3CCCCC3)CC2)c1Cl JDADDZFCNPRPPP-MXVIHJGJSA-N 0.000 claims 1
- DVSSJNOOZGUAPL-WGSAOQKQSA-N Clc1cccc(N2CCN(CC[C@H]3CC[C@@H](CC3)NC(=O)N3CCNCC3)CC2)c1Cl Chemical compound Clc1cccc(N2CCN(CC[C@H]3CC[C@@H](CC3)NC(=O)N3CCNCC3)CC2)c1Cl DVSSJNOOZGUAPL-WGSAOQKQSA-N 0.000 claims 1
- SGPIDOUGTPWWNZ-WGSAOQKQSA-N Clc1cccc(N2CCN(CC[C@H]3CC[C@@H](CC3)NC(=O)N3CCOCC3)CC2)c1Cl Chemical compound Clc1cccc(N2CCN(CC[C@H]3CC[C@@H](CC3)NC(=O)N3CCOCC3)CC2)c1Cl SGPIDOUGTPWWNZ-WGSAOQKQSA-N 0.000 claims 1
- NGSXLQFECJAMGF-AOJGPSJRSA-N Clc1cccc(N2CCN(CC[C@H]3CC[C@@H](CC3)NC(=O)NC34CC5CC(CC(C5)C3)C4)CC2)c1Cl Chemical compound Clc1cccc(N2CCN(CC[C@H]3CC[C@@H](CC3)NC(=O)NC34CC5CC(CC(C5)C3)C4)CC2)c1Cl NGSXLQFECJAMGF-AOJGPSJRSA-N 0.000 claims 1
- GZHQKERJJYVCIH-XUTJKUGGSA-N Clc1cccc(N2CCN(CC[C@H]3CC[C@@H](CC3)NC(=O)NC3CCCCC3)CC2)c1Cl Chemical compound Clc1cccc(N2CCN(CC[C@H]3CC[C@@H](CC3)NC(=O)NC3CCCCC3)CC2)c1Cl GZHQKERJJYVCIH-XUTJKUGGSA-N 0.000 claims 1
- YPMKRVRICVAIGR-AQYVVDRMSA-N Clc1cccc(N2CCN(CC[C@H]3CC[C@@H](CC3)NC(=O)NCc3ccccc3)CC2)c1Cl Chemical compound Clc1cccc(N2CCN(CC[C@H]3CC[C@@H](CC3)NC(=O)NCc3ccccc3)CC2)c1Cl YPMKRVRICVAIGR-AQYVVDRMSA-N 0.000 claims 1
- CTTPYAARTQLSEP-XUTJKUGGSA-N Clc1cccc(N2CCN(CC[C@H]3CC[C@@H](CC3)NC(=O)Nc3cccc(c3)C#N)CC2)c1Cl Chemical compound Clc1cccc(N2CCN(CC[C@H]3CC[C@@H](CC3)NC(=O)Nc3cccc(c3)C#N)CC2)c1Cl CTTPYAARTQLSEP-XUTJKUGGSA-N 0.000 claims 1
- HJPIWYMRQVSMJC-XUTJKUGGSA-N Clc1cccc(N2CCN(CC[C@H]3CC[C@@H](CC3)NC(=O)Nc3ccccc3)CC2)c1Cl Chemical compound Clc1cccc(N2CCN(CC[C@H]3CC[C@@H](CC3)NC(=O)Nc3ccccc3)CC2)c1Cl HJPIWYMRQVSMJC-XUTJKUGGSA-N 0.000 claims 1
- DYIZZOLJGDPLPD-ALOJWSFFSA-N Clc1cccc(N2CCN(CC[C@H]3CC[C@@H](CC3)NC(=O)Nc3ccccc3-c3ccccc3)CC2)c1Cl Chemical compound Clc1cccc(N2CCN(CC[C@H]3CC[C@@H](CC3)NC(=O)Nc3ccccc3-c3ccccc3)CC2)c1Cl DYIZZOLJGDPLPD-ALOJWSFFSA-N 0.000 claims 1
- PXDJAKABAZDZKM-XUTJKUGGSA-N Clc1cccc(N2CCN(CC[C@H]3CC[C@@H](CC3)NC(=S)NC(=O)c3ccccc3)CC2)c1Cl Chemical compound Clc1cccc(N2CCN(CC[C@H]3CC[C@@H](CC3)NC(=S)NC(=O)c3ccccc3)CC2)c1Cl PXDJAKABAZDZKM-XUTJKUGGSA-N 0.000 claims 1
- OMGOPTSNMNUWJL-AOJGPSJRSA-N Clc1cccc(N2CCN(CC[C@H]3CC[C@@H](CC3)NC(=S)NC34CC5CC(CC(C5)C3)C4)CC2)c1Cl Chemical compound Clc1cccc(N2CCN(CC[C@H]3CC[C@@H](CC3)NC(=S)NC34CC5CC(CC(C5)C3)C4)CC2)c1Cl OMGOPTSNMNUWJL-AOJGPSJRSA-N 0.000 claims 1
- ABWSTENPYXDJLL-AQYVVDRMSA-N Clc1cccc(N2CCN(CC[C@H]3CC[C@@H](CC3)NC(=S)NCc3ccccc3)CC2)c1Cl Chemical compound Clc1cccc(N2CCN(CC[C@H]3CC[C@@H](CC3)NC(=S)NCc3ccccc3)CC2)c1Cl ABWSTENPYXDJLL-AQYVVDRMSA-N 0.000 claims 1
- CYKUGALPZQQFQI-AFARHQOCSA-N Clc1cccc(N2CCN(CC[C@H]3CC[C@@H](CC3)NC(=S)Nc3cccc4ccccc34)CC2)c1Cl Chemical compound Clc1cccc(N2CCN(CC[C@H]3CC[C@@H](CC3)NC(=S)Nc3cccc4ccccc34)CC2)c1Cl CYKUGALPZQQFQI-AFARHQOCSA-N 0.000 claims 1
- VVEKUOJKZUYLOE-XUTJKUGGSA-N Clc1cccc(N2CCN(CC[C@H]3CC[C@@H](CC3)NC(=S)Nc3ccccc3)CC2)c1Cl Chemical compound Clc1cccc(N2CCN(CC[C@H]3CC[C@@H](CC3)NC(=S)Nc3ccccc3)CC2)c1Cl VVEKUOJKZUYLOE-XUTJKUGGSA-N 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000024254 Delusional disease Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- DBDFCGCQVAECDX-WGSAOQKQSA-N FC(F)(F)Oc1ccc(NC(=O)N[C@H]2CC[C@H](CCN3CCN(CC3)c3cccc(Cl)c3Cl)CC2)cc1 Chemical compound FC(F)(F)Oc1ccc(NC(=O)N[C@H]2CC[C@H](CCN3CCN(CC3)c3cccc(Cl)c3Cl)CC2)cc1 DBDFCGCQVAECDX-WGSAOQKQSA-N 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 1
- UMTWXZNVNBBFLC-SHTZXODSSA-N NC(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 Chemical compound NC(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 UMTWXZNVNBBFLC-SHTZXODSSA-N 0.000 claims 1
- BZORKKASQXFJHM-WGSAOQKQSA-N OC1CCN(CC1)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 Chemical compound OC1CCN(CC1)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 BZORKKASQXFJHM-WGSAOQKQSA-N 0.000 claims 1
- 208000027099 Paranoid disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims 1
- 230000016571 aggressive behavior Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- NBYQXBYMEUOBON-UHFFFAOYSA-N carbamothioyl chloride Chemical compound NC(Cl)=S NBYQXBYMEUOBON-UHFFFAOYSA-N 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- CLYLEOXSUSFWBW-WGSAOQKQSA-N chembl2024519 Chemical compound C1C[C@@H](NC(=O)N(CC)CC)CC[C@@H]1CCN1CCN(C=2C(=C(Cl)C=CC=2)Cl)CC1 CLYLEOXSUSFWBW-WGSAOQKQSA-N 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 150000001913 cyanates Chemical class 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 230000000142 dyskinetic effect Effects 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 239000003176 neuroleptic agent Substances 0.000 claims 1
- 230000000701 neuroleptic effect Effects 0.000 claims 1
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/04—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0302451A HU227534B1 (en) | 2003-08-04 | 2003-08-04 | (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them |
PCT/HU2004/000056 WO2005012266A1 (en) | 2003-08-04 | 2004-05-21 | (thio) carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20120715T1 true HRP20120715T1 (hr) | 2012-09-30 |
Family
ID=89981557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20120715TT HRP20120715T1 (hr) | 2003-08-04 | 2012-09-07 | Derivati (tio)karbamoil-cikloheksana kao antagonisti d3/d2 receptora |
Country Status (37)
Country | Link |
---|---|
US (2) | US7737142B2 (bs) |
EP (1) | EP1663996B1 (bs) |
JP (1) | JP3999806B2 (bs) |
KR (1) | KR100870284B1 (bs) |
CN (1) | CN1829703B (bs) |
AU (1) | AU2004261490B2 (bs) |
BE (1) | BE2017C045I2 (bs) |
BR (1) | BRPI0413283B8 (bs) |
CA (1) | CA2532818C (bs) |
CY (2) | CY1113099T1 (bs) |
DK (1) | DK1663996T3 (bs) |
EA (1) | EA009022B1 (bs) |
ES (1) | ES2389840T3 (bs) |
FR (1) | FR17C0008I1 (bs) |
HK (1) | HK1093494A1 (bs) |
HR (1) | HRP20120715T1 (bs) |
HU (2) | HU227534B1 (bs) |
IL (1) | IL172746A (bs) |
IS (1) | IS2905B (bs) |
LT (1) | LTC1663996I2 (bs) |
LU (1) | LUC00039I2 (bs) |
MA (1) | MA28024A1 (bs) |
ME (1) | ME00564A (bs) |
MX (1) | MXPA06001033A (bs) |
MY (1) | MY142760A (bs) |
NL (1) | NL300913I2 (bs) |
NO (2) | NO334973B1 (bs) |
NZ (1) | NZ544999A (bs) |
PL (1) | PL1663996T3 (bs) |
PT (1) | PT1663996E (bs) |
RS (1) | RS52771B (bs) |
SI (1) | SI1663996T1 (bs) |
TN (1) | TNSN05328A1 (bs) |
TW (1) | TWI327141B (bs) |
UA (1) | UA84022C2 (bs) |
WO (1) | WO2005012266A1 (bs) |
ZA (1) | ZA200601026B (bs) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007106746A (ja) * | 2005-09-13 | 2007-04-26 | Tosoh Corp | 新規アリールホモピペラジン類、またはその塩と製造方法 |
EP1870405A1 (en) * | 2006-06-22 | 2007-12-26 | Bioprojet | Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands |
ES2401663T3 (es) * | 2006-10-31 | 2013-04-23 | F. Hoffmann-La Roche Ag | Derivados éter moduladores duales de los receptores de 5-HT2a y D3 |
HUP0700269A2 (en) * | 2007-04-11 | 2009-04-28 | Richter Gedeon Nyrt | Pyrimidinyl-piperazines useful as d3/d2 receptor ligands, pharmaceutical compositions containing them and their use |
HU230748B1 (hu) * | 2007-05-11 | 2018-02-28 | Richter Gedeon Nyrt | Új piperazin só és előállítási eljárása |
MY148643A (en) * | 2007-05-11 | 2013-05-15 | Richter Gedeon Nyrt | Solvate and crystalline forms of carbamoyl-cyclohexane derivatives |
HUP0700353A2 (en) * | 2007-05-18 | 2008-12-29 | Richter Gedeon Nyrt | Metabolites of (thio)carbamoyl-cyclohexane derivatives |
HUP0700369A2 (en) * | 2007-05-24 | 2009-04-28 | Richter Gedeon Nyrt | Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment in the manufacture of a medicament for the treatment of schizophrenia |
HUP0700370A2 (en) * | 2007-05-24 | 2009-04-28 | Richter Gedeon Nyrt | Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment of acute mania |
JP5460594B2 (ja) * | 2007-08-03 | 2014-04-02 | リチュテル・ゲデオン・ヴェジェーセティ・ジャール・ニュイルヴァーノシャン・ミューコェデー・レースヴェーニュタールシャシャーグ | ドーパミン受容体リガンドを含有する医薬組成物およびドーパミン受容体リガンドを用いる処置方法 |
US7875610B2 (en) | 2007-12-03 | 2011-01-25 | Richter Gedeon Nyrt. | Pyrimidinyl-piperazines useful as D3/D2 receptor ligands |
ATE552002T1 (de) * | 2008-02-21 | 2012-04-15 | Richter Gedeon Nyrt | Feste zubereitung zur oralen verabreichung |
US20090275597A1 (en) * | 2008-05-02 | 2009-11-05 | Forest Laboratories Holdings Limited | Methods of treating cns disorders |
EP2317852B1 (en) * | 2008-07-16 | 2014-12-24 | Richter Gedeon Nyrt. | Pharmaceutical formulations containing dopamine receptor ligands |
HU230067B1 (hu) * | 2008-12-17 | 2015-06-29 | Richter Gedeon Nyrt | Új piperazin só és eljárás előállítására |
HUP0800766A2 (en) * | 2008-12-18 | 2010-11-29 | Richter Gedeon Vegyeszet | Process for the preparation of piperazine derivatives |
HUP0800765A2 (en) | 2008-12-18 | 2010-11-29 | Richter Gedeon Nyrt | A new process for the preparation of piperazine derivatives and their hydrochloric salts |
WO2010126527A1 (en) * | 2009-05-01 | 2010-11-04 | Forest Laboratories Holdings Limited | Methods of treating cns disorders |
WO2011060363A2 (en) * | 2009-11-16 | 2011-05-19 | Auspex Pharmaceuticals, Inc. | Cyclohexyl urea modulators of d2 receptors and/or d3 receptors |
HUP0900790A2 (en) | 2009-12-17 | 2011-09-28 | Richter Gedeon Nyrt | A new process for the preparation of piperazine and their hydrochloric salts |
CN103130737B (zh) * | 2011-12-05 | 2015-12-02 | 江苏恒谊药业有限公司 | 环己烷胺类化合物及其作为抗精神分裂症药物的应用 |
US8912197B2 (en) | 2012-08-20 | 2014-12-16 | Forest Laboratories Holdings Ltd. | Crystalline form of carbamoyl-cyclohexane derivatives |
CN104755083B (zh) * | 2012-10-11 | 2018-04-10 | 南方研究所 | 氨基烷基哌嗪的脲和酰胺衍生物及其用途 |
HU231227B1 (hu) | 2012-11-29 | 2022-03-28 | Richter Gedeon Nyrt. | Transz-4-{2-[4-(2,3-diklórfenil)-piperazin-1-il]-etil}N,N-dimetilkarbamoil-ciklohexilamin skizofrénia negatív tüneteinek kezelésére |
ITMI20131693A1 (it) | 2013-10-14 | 2015-04-15 | Chemo Res S L | Derivati della 1,4-cicloesilammina e loro preparazione |
CN105085345B (zh) * | 2015-08-14 | 2016-09-14 | 天津小新医药科技有限公司 | 含硝基的l-薄荷醇类p2y12受体拮抗剂及其用途 |
CN105085346B (zh) * | 2015-08-14 | 2017-03-29 | 天津小新医药科技有限公司 | 含胺基的l-薄荷醇类p2y12受体拮抗剂及其用途 |
CN105218484B (zh) * | 2015-09-14 | 2018-02-23 | 安徽省逸欣铭医药科技有限公司 | 酒石酸卡利拉嗪及其制备方法和医药用途 |
CN106518841B (zh) * | 2015-09-15 | 2019-03-05 | 浙江京新药业股份有限公司 | 环己烷衍生物或其立体异构体或盐及其制备与应用 |
CN106543039A (zh) * | 2015-09-22 | 2017-03-29 | 江苏恩华药业股份有限公司 | 一种用于制备卡利拉嗪的化合物及其制备方法 |
CN106560179B (zh) * | 2015-09-30 | 2020-02-21 | 石药集团中奇制药技术(石家庄)有限公司 | 盐酸卡利拉嗪药物组合物及其制备方法 |
CN105330616B (zh) * | 2015-12-09 | 2017-09-26 | 苏州明锐医药科技有限公司 | 卡利拉嗪的制备方法 |
EP3231418A1 (en) | 2016-04-14 | 2017-10-18 | Richter Gedeon Nyrt. | Granule formulation for oral administration |
US11274087B2 (en) | 2016-07-08 | 2022-03-15 | Richter Gedeon Nyrt. | Industrial process for the preparation of cariprazine |
HU231173B1 (hu) | 2016-07-08 | 2021-06-28 | Richter Gedeon Nyrt. | Ipari eljárás cariprazine előállítására |
US10870660B2 (en) | 2016-07-28 | 2020-12-22 | Shionogi & Co., Ltd. | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect |
CN107793350B (zh) * | 2016-09-05 | 2021-06-04 | 上海医药工业研究院 | 芳乙基哌啶基衍生物及其治疗精神分裂症的应用 |
WO2018229794A1 (en) | 2017-06-13 | 2018-12-20 | Cipla Limited | Amorphous form of cariprazine |
HUP1700253A1 (hu) | 2017-06-13 | 2019-01-28 | Richter Gedeon Nyrt | Szilárd orális gyógyszerkészítmények |
JP7250405B2 (ja) | 2018-01-26 | 2023-04-03 | 塩野義製薬株式会社 | ドーパミンd3受容体拮抗作用を有する環式化合物 |
JPWO2019146739A1 (ja) | 2018-01-26 | 2021-01-07 | 塩野義製薬株式会社 | ドーパミンd3受容体拮抗作用を有する縮環化合物 |
CN108586389B (zh) * | 2018-06-29 | 2020-06-12 | 成都福柯斯医药技术有限公司 | 一种合成卡利拉嗪的方法 |
CN110872262A (zh) | 2018-08-29 | 2020-03-10 | 上海科胜药物研发有限公司 | 一种卡利拉嗪的合成方法 |
CN110872269B (zh) * | 2018-08-30 | 2024-06-07 | 浙江京新药业股份有限公司 | 一种环己烷衍生物的盐 |
CN110872270A (zh) * | 2018-08-30 | 2020-03-10 | 浙江京新药业股份有限公司 | 一种环己烷衍生物的盐 |
CN111320594A (zh) * | 2018-12-13 | 2020-06-23 | 江苏恩华药业股份有限公司 | 一种卡利拉嗪杂质及其制备工艺和用途 |
HU231500B1 (hu) * | 2019-04-10 | 2024-04-28 | Richter Gedeon Nyrt | Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére |
US11547707B2 (en) | 2019-04-10 | 2023-01-10 | Richter Gedeon Nyrt. | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder |
CN112239433B (zh) * | 2019-07-17 | 2024-05-14 | 北京盈科瑞创新药物研究有限公司 | 一种环己烷衍生物、制备方法及其应用 |
CN110372557B (zh) * | 2019-08-06 | 2021-05-18 | 上海勋和医药科技有限公司 | 环己烷胺类d3/d2受体部分激动剂 |
WO2021083246A1 (zh) | 2019-10-29 | 2021-05-06 | 上海翰森生物医药科技有限公司 | 四元环类衍生物调节剂、其制备方法和应用 |
KR20220119013A (ko) * | 2019-11-05 | 2022-08-26 | 상하이 한서 바이오메디컬 컴퍼니 리미티드 | 벤조티오펜 유도체 조절제, 그의 제조 방법 및 그의 용도 |
HUP2100108A1 (hu) | 2021-03-12 | 2022-09-28 | Richter Gedeon Nyrt | Eljárás és berendezés gyógyászatilag alkalmazható piperazin származékok folyamatos áramú, áramlásos konszekutív redukálással történõ elõállítására |
KR20240005786A (ko) | 2021-04-28 | 2024-01-12 | 상하이 한서 바이오메디컬 컴퍼니 리미티드 | 피페라진 폴리사이클릭 유도체를 함유하는 염, 이의 결정형, 이의 제조 방법, 및 이의 용도 |
HUP2100259A1 (hu) | 2021-07-07 | 2023-01-28 | Richter Gedeon Nyrt | Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények |
EP4402276A1 (en) | 2021-09-15 | 2024-07-24 | Richter Gedeon Nyrt. | Process to produce (1 r, 4 r)-4-substituted cyclohexane-1-amines |
HUP2200312A1 (hu) | 2022-08-05 | 2024-02-28 | Richter Gedeon Nyrt | Kariprazin tartalmú szájban diszpergálódó tabletta |
WO2024072930A1 (en) * | 2022-09-30 | 2024-04-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dopamine d3/d2 receptor partial agonists for the treatment of neuropsychiatric disorders |
EP4400495A1 (en) | 2023-01-11 | 2024-07-17 | Richter Gedeon Nyrt. | Dopamine d3/d2 receptor modulating compounds |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6859096A (en) | 1995-09-22 | 1997-04-09 | Warner-Lambert Company | Substituted cyclohexylamines as central nervous system agents |
US6528529B1 (en) * | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
CN1303376A (zh) | 1998-03-31 | 2001-07-11 | 阿卡蒂亚药品公司 | 对毒蕈碱性受体具有活性的化合物 |
SE9802208D0 (sv) | 1998-06-22 | 1998-06-22 | Astra Pharma Inc | Novel compounds |
HU227543B1 (en) * | 2001-09-28 | 2011-08-29 | Richter Gedeon Nyrt | N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them |
-
2003
- 2003-08-04 HU HU0302451A patent/HU227534B1/hu unknown
-
2004
- 2004-05-21 CA CA002532818A patent/CA2532818C/en not_active Expired - Fee Related
- 2004-05-21 BR BRPI0413283A patent/BRPI0413283B8/pt active IP Right Grant
- 2004-05-21 MX MXPA06001033A patent/MXPA06001033A/es active IP Right Grant
- 2004-05-21 CN CN2004800219507A patent/CN1829703B/zh not_active Expired - Lifetime
- 2004-05-21 UA UAA200600942A patent/UA84022C2/ru unknown
- 2004-05-21 ME MEP-849/08A patent/ME00564A/xx unknown
- 2004-05-21 NZ NZ544999A patent/NZ544999A/en unknown
- 2004-05-21 PT PT04734301T patent/PT1663996E/pt unknown
- 2004-05-21 JP JP2006522421A patent/JP3999806B2/ja not_active Expired - Lifetime
- 2004-05-21 ES ES04734301T patent/ES2389840T3/es not_active Expired - Lifetime
- 2004-05-21 WO PCT/HU2004/000056 patent/WO2005012266A1/en active Application Filing
- 2004-05-21 AU AU2004261490A patent/AU2004261490B2/en active Active
- 2004-05-21 KR KR1020067002364A patent/KR100870284B1/ko active IP Right Grant
- 2004-05-21 DK DK04734301.7T patent/DK1663996T3/da active
- 2004-05-21 PL PL04734301T patent/PL1663996T3/pl unknown
- 2004-05-21 RS RS20060041A patent/RS52771B/en unknown
- 2004-05-21 EA EA200600364A patent/EA009022B1/ru active Protection Beyond IP Right Term
- 2004-05-21 EP EP04734301A patent/EP1663996B1/en not_active Expired - Lifetime
- 2004-05-21 SI SI200431919T patent/SI1663996T1/sl unknown
- 2004-06-01 TW TW093115688A patent/TWI327141B/zh active
- 2004-06-07 MY MYPI20042187A patent/MY142760A/en unknown
-
2005
- 2005-12-21 IL IL172746A patent/IL172746A/en active Protection Beyond IP Right Term
- 2005-12-22 IS IS8199A patent/IS2905B/is unknown
- 2005-12-23 TN TNP2005000328A patent/TNSN05328A1/en unknown
-
2006
- 2006-01-20 US US11/337,275 patent/US7737142B2/en active Active
- 2006-02-03 ZA ZA200601026A patent/ZA200601026B/en unknown
- 2006-03-03 MA MA28855A patent/MA28024A1/fr unknown
- 2006-03-06 NO NO20061076A patent/NO334973B1/no active Protection Beyond IP Right Term
-
2007
- 2007-01-04 HK HK07100087.7A patent/HK1093494A1/xx unknown
-
2010
- 2010-05-12 US US12/779,014 patent/US20100240640A1/en not_active Abandoned
-
2012
- 2012-09-07 HR HRP20120715TT patent/HRP20120715T1/hr unknown
- 2012-09-10 CY CY20121100815T patent/CY1113099T1/el unknown
-
2017
- 2017-08-24 LT LTPA2017027C patent/LTC1663996I2/lt unknown
- 2017-10-09 NO NO2017051C patent/NO2017051I2/no unknown
- 2017-10-10 LU LU00039C patent/LUC00039I2/en unknown
- 2017-10-10 FR FR17C0008C patent/FR17C0008I1/fr active Active
- 2017-10-18 CY CY2017032C patent/CY2017032I2/el unknown
- 2017-11-02 HU HUS1700044C patent/HUS1700044I1/hu unknown
- 2017-11-14 BE BE2017C045C patent/BE2017C045I2/fr unknown
- 2017-11-17 NL NL300913C patent/NL300913I2/nl unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20120715T1 (hr) | Derivati (tio)karbamoil-cikloheksana kao antagonisti d3/d2 receptora | |
DK2297120T3 (en) | Aminodihydrothiazine derivatives as bace inhibitors for the treatment of Alzheimer's disease | |
EP0395312B1 (en) | Piperazine derivatives | |
US7812040B2 (en) | Histamine-3 receptor antagonists | |
DE69200893T2 (de) | Piperazinederivate. | |
ES2407182T3 (es) | Procedimiento de preparación de compuestos de piperacina y sales clorhídricas de los mismos | |
US6284759B1 (en) | 2-piperazinoalkylaminobenzo-azole derivatives: dopamine receptor subtype specific ligands | |
SK80993A3 (en) | Benzamides | |
PL211096B1 (pl) | Pochodne indolu, środek farmaceutyczny, zastosowanie pochodnych indolu i związki pośrednie | |
DE60102357T2 (de) | Verfahren zur herstellung von quetiapin und intermediate dafür | |
CA2125182A1 (en) | Piperazine derivatives as 5-ht receptors antagonists | |
JP2008508351A5 (bs) | ||
DE69104041T4 (de) | Orthosubstituierte biphenylguanidinderivate sowie diese enthaltende antidiabetische oder hypoglykämische mittel. | |
NZ272001A (en) | Substituted 5-(phenyl)-pyrimidine derivatives and medicaments | |
DE602004010820T2 (de) | Verfahren zur herstellung von 4-aryl-nicotinamidderivaten | |
DE69829989T2 (de) | 1-(2-naphthyl) und 1-(2-azanaphthyl)-4-(1-phenylmethyl)piperazine als dopamin d4 subtype liganden | |
US5340812A (en) | Piperazine derivatives | |
WO1997011070A1 (en) | Substituted cyclohexylamines as central nervous system agents | |
RU2052452C1 (ru) | Амидиновые производные бензола и их фармацевтически приемлемые соли | |
US5420278A (en) | ω-(4-aryl or heteroarylpiperazine-1-yl)-2-aryl or aralkyl-propanoic or butanoic acids | |
US5541326A (en) | Piperazine Derivatives | |
SK282841B6 (sk) | Derivát 4-(1-piperazinyl)benzoovej kyseliny, spôsob jeho prípravy a jeho farmaceutický prostriedok, ktorý ho obsahuje | |
DE69818079T2 (de) | Verfahren zur herstellung von piperazinsulfonamid-derivaten und ihren salzen | |
EP0536169B1 (en) | [3H,7H]THIAZOLO [3,4-a]PYRIDINES WITH ANTIASTHMATIC AND ANTIINFLAMMATORY ACTIONS ON THE RESPIRATORY TRACT | |
MXPA06005239A (en) | Novel phenyl-pyridinyl-piperazine derivatives, a method for the production thereof and pharmaceutical compositions containing said derivatives |